Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 sept. 2014 15h01 HE | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today provided an update on the Company's innovative ESKAPE Pathogen Program. The ESKAPE Pathogen Program leverages Melinta's...
08 sept. 2014 11h01 HE | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results from in vitro studies that highlight the potential of delafloxacin, an investigational fluoroquinolone,...
06 sept. 2014 12h01 HE | Source: Melinta Therapeutics

Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens

NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Hartford Hospital today announced in vitro results from an investigator-sponsored study that highlight delafloxacin's...
06 sept. 2014 12h01 HE | Source: Melinta Therapeutics

Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program

NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that...
04 sept. 2014 10h45 HE | Source: Melinta Therapeutics

Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting

NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that an additional three abstracts have been accepted as late-breakers at the annual Interscience Conference...
11 août 2014 12h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration

NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced top-line results of a Phase 1 clinical study that demonstrated that the administration of single doses of...
24 juil. 2014 08h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that the company and investigators will be making eight presentations at the annual Interscience Conference...
17 juin 2014 14h00 HE | Source: Melinta Therapeutics

Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference

NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that CEO Mary Szela will be presenting at the annual JMP Securities Healthcare Conference in New York, NY....
05 mai 2014 11h27 HE | Source: Melinta Therapeutics

Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections

NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that patient enrollment has commenced in a Phase 3 trial of oral and intravenous (I.V.) delafloxacin, a...
03 avr. 2014 14h38 HE | Source: Melinta Therapeutics

Melinta Therapeutics to Present at Needham & Company's Annual Healthcare Conference

NEW HAVEN, Conn, April 3, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Mary Szela, the Company's chief executive officer, will be presenting a corporate update at Needham...

Page précédente

Page suivante